The Food and Drug Administration USA (FDA) authorized updated vaccines against against the new variants of COVID-19 which are in circulation in almost every country, most of them Omicron, which are intended to reduce hospitalizations and deaths.
A statement said: FDA indicates that the approved vaccines They are mRNA updated for 2023-2024 and are manufactured by Moderna and Pfizer. In accordance with the totality of the evidence and the contributions of the expert advisors of the FDAThese vaccines have been updated to contain a monovalent (single) component corresponding to the Omicron variant XBB.1.5.
According to the FDAPeople over the age of five can receive a dose of the updated vaccine at least two months after the last dose of a vaccine COVID-19.
“Vaccinations remain critical to public health and continued protection against the serious consequences of Covid-19, including hospitalizations and deaths,” said Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research.
“The public can be assured that these updated vaccines meet the agency’s rigorous scientific standards for safety, effectiveness and manufacturing quality. “We strongly encourage those who are eligible to consider vaccination,” he added.
Reports of cases of an Omicron subtype are increasing in the United States
The authorization of the FDA This comes after a spike in cases in late summer, at a time when the new EG.5 subvariant of Omicron – nicknamed “Eris” – began to spread rapidly USA and in other parts of the world.
Advisers from the US Centers for Disease Control and Prevention (CDC) are scheduled to meet on Tuesday, September 12, to recommend who should receive the vaccine.
The soon-expected approval from CDC Director Mandy Cohen should clear the way for the new vaccines. Cohen has said he expects the vaccines to begin rolling out in September.